Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore

被引：0
|
作者：
Chay, J. [1 ]
Su, R. [1 ]
Tung, J. Y. M. [2 ]
Aslim, E. J. [2 ]
Wong, C. [3 ]
Swan, G.
Chua, W. J. [4 ]
Ho, S. S. H. [2 ]
Finkelstein, E. A. [1 ]
机构：
[1] Duke NUS Med Sch, Hlth Serv & Syst Res, Singapore, Singapore
[2] Singapore Gen Hosp, Dept Urol, Singapore, Singapore
[3] Boston Sci, Asia Pacific, Hlth Econ & Market Access, Singapore, Singapore
[4] Natl Univ Singapore Hosp, Dept Urol, Singapore, Singapore
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0034
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [31] Evaluation of the Cost-Effectiveness of Surgical Treatment Options for Benign Prostatic Hyperplasia EDITORIAL COMMENT
    Higgins, Andrew M.
    Dauw, Casey A.
    UROLOGY, 2023, 171 : 102 - 102
  • [32] COST-EFFECTIVENESS ANALYSIS OF DUTASTERIDE, TAMSULOSIN AND COMBINATION THERAPY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    Bang, S., I
    Hay, J.
    VALUE IN HEALTH, 2010, 13 (03) : A78 - A78
  • [33] Coronary angiography: first- or second-line examination?
    Danchin, N
    Angioi, M
    Fattah, IA
    Jacquemin, L
    ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE, 1997, 46 (08): : 493 - 497
  • [34] Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study
    Ichihara, Koji
    Masumori, Naoya
    Iwasawa, Akihiko
    Taguchi, Keisuke
    Yamaguchi, Yasuhiro
    Nishimura, Masahiro
    Sasamura, Hiroto
    Suzuki, Nobukazu
    Haga, Kazunori
    Miyao, Noriomi
    Hirose, Takaoki
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (10) : 849 - 854
  • [35] Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan
    Munenobu Kashiwa
    The European Journal of Health Economics, 2024, 25 : 459 - 470
  • [36] Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan
    Kashiwa, Munenobu
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (03): : 459 - 470
  • [37] Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia
    Goshua, George
    Sinha, Pranay
    Kunst, Natalia
    Pischel, Lauren
    Lee, Alfred Ian
    Cuker, Adam
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (01) : 122 - 130
  • [38] Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
    Peral, Carmen
    Cordido, Fernando
    Gimeno-Ballester, Vicente
    Mir, Nuria
    Sanchez-Cenizo, Laura
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (01) : 105 - 114
  • [39] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [40] Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
    Soto-Perez-de-Celis, Enrique
    Aguiar, Pedro N., Jr.
    Cordon, Monica L.
    Chavarri-Guerra, Yanin
    Lopes, Gilberto de Lima, Jr.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 669 - 675
12345